https://www.selleckchem.com/pr....oducts/glesatinib.ht
Of 93 included individuals (mean age 62.6±11years), 52 (56%) had a history of mild symptomatic SARS-CoV-2 infection. Post-pandemic MoCA decay was worse in seropositive individuals. Cognitive decline was recognized in 11/52 (21%) seropositive and 1/41 (2%) seronegative individuals. In multivariate analyses, the odds for developing cognitive decline were 18.1 times higher among SARS-CoV-2 seropositive individuals (95% confidence interval 1.75-188; p=0.015). Exposure-effect models confirmed this association (β = 0.24; 95% confidence int
Like
Comment
Share
